

Attorney Docket P1752R1

PATENT

## **CERTIFICATION UNDER 37 CFR 1.10**

EM 168 883 307 US: Express Mail Number

July 10, 2000: Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Ann Savelli

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION Assistant Commissioner of Patents Washington, D.C. 20231

# NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Antonio J. Grillo-Lopez, Rancho Santa Fe, CA Lori A. Kunkel, Oakland, CA Timothy A. Stewart, San Francisco, CA

Title:

# **BLOCKING IMMUNE RESPONSE TO A FOREIGN ANTIGEN**

- 1. Type of Application
- [ ] This application is for an original, non-provisional application.
- [x ] This is a non-provisional application claiming priority to provisional application no. 60/144,405 , filed <u>July 16, 1999</u>, the entire disclosure of which is hereby incorporated by reference.
- [ ] This is a [ ] continuation-in-part [ ] continuation [ ] divisional application claiming priority to application Serial Number\_\_, filed \_\_\_, the entire disclosure of which is hereby incorporated by reference.
- Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional)
  - 48 pages of specification
  - 4 pages of claims
  - \_\_\_\_\_ page(s) of abstract
  - o sheet(s) of drawings
    [] formal [] informal

3.	Declaration or Oath
	<ul> <li>(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)</li> <li>_x An unsigned declaration of the inventors is enclosed. A signed declaration of the inventors will follow.</li> </ul>
	<ul> <li>(for Cont./Div. where inventorship is the same or inventor(s) being deleted)</li> <li>A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).</li> </ul>
	(for Cont./Div. where inventor(s) being deleted)  A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).
4.	Assignment
	(for new and CIP applications)  _x An Assignment of the invention to GENENTECH, INC. and IDEC PHARMACEUTICALS, INC. will follow.
	(for cont./div.)  The prior application is assigned of record to Genentech, Inc.
5.	Amendments (for continuation and divisional applications)
	Cancel in this application original claims of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
	A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)
	Relate Back 35 U.S.C. 120 or 35 U.S.C. 119
	Amend the specification by inserting before the first line the sentence:
	This is a
	non-provisional application continuation divisional continuation-in-part
	of co-pending application(s)
	Serial No filed on_, which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120

 Internation	onal A	\ppli	catio	n_fi	iled o	on	_whic	h de	sigr	nated	the U	.S.	, wl	hich	арр	licat	ion(s	) is(	(are)
incorpora	ated h	erei	n by i	refer	ence	and	d to wi	nich :	арр	licatio	n(s) p	rio	rity	is c	laim	ed u	nder	35 (	JSC
§120																			

provisional application No. \_ filed \_, the entire disclosure of which is hereby incorporated by reference and to which application(s) priority is claimed under 35 USC §119.--.

#### 6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

		CLAIN	S FOR FEE CA	LCULATION			
Number	Filed	Numb	er Extra	Rate	Basic Fee 37 CFR 1.16(a)		
					\$690.00		
Total Claims	31	- 20 =	11	X \$18.00	\$198.00		
Independent Claims	5	- 3=	2	X \$78.00	\$156.00		
	Multiple d	ependent claim	+ \$260.00	\$0.00			
	\$1,044.00						

### 7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$1,044.00. A duplicate copy of this transmittal is enclosed.

### 8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

### 9. Additional Papers Enclosed

- [] Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- [] Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- [] A new Power of Attorney or authorization of agent.
- [] Other:

10.	Maintenance	of	Copendency	of	Prior	Application	(for	continuation	and	divisional
applica	ations)									

[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]

A 4141				
A petition	tee and/or	response has	s been tiled to	extend the term in

 the pending prior application until A copy of the petition for extension of time in the *prior* application is attached.

#### Correspondence Address: 11.

Address all future communications to: <u>X</u>

> GENENTECH, INC. Attn: Wendy Lee 1 DNA Way South San Francisco, CA 94080-4990 (650) 225-1994

> > Respectfully submitted, GENENTECH, INC.

Wendy Lee

Reg. No. 40,378

Date: July 10, 2000

1 DNA Way

So. San Francisco, CA 94080-4990

Phone: (650) 225-1994 Fax: (650) 952-9881